Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-label, Multi-center, Safety and Tolerability Study of a Single Dose of 68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)

NCT03490032 is registered in ClinicalTrials.gov with Advanced Accelerator Applications as lead sponsor.

NCT NCT03490032
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03490032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-label, Multi-center, Safety and Tolerability Study of a Single Dose of 68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)
Lead sponsor
Advanced Accelerator Applications
Phase
Phase 1/2
Overall status
Completed
Start date
May 23, 2018
Completion date
September 13, 2019
Enrollment
30 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer metastatic